Arvinas (ARVN) to Release Quarterly Earnings on Tuesday

Arvinas (NASDAQ:ARVN) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.24) per share and revenue of $60.7080 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Monday, May 11th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.05. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The business had revenue of $15.60 million during the quarter, compared to the consensus estimate of $16.61 million. During the same quarter in the previous year, the firm posted $1.14 EPS. Arvinas’s revenue was down 91.7% compared to the same quarter last year. On average, analysts expect Arvinas to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Performance

Shares of ARVN opened at $8.03 on Friday. Arvinas has a 52 week low of $6.05 and a 52 week high of $14.51. The firm has a market cap of $518.10 million, a P/E ratio of -2.42 and a beta of 1.74. The firm’s 50-day simple moving average is $8.09 and its 200 day simple moving average is $10.37.

Insider Activity

In related news, CEO Randy Teel sold 9,657 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the completion of the transaction, the chief executive officer owned 287,218 shares of the company’s stock, valued at $2,854,946.92. The trade was a 3.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Noah Berkowitz sold 11,108 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $110,413.52. Following the completion of the transaction, the insider owned 191,395 shares of the company’s stock, valued at $1,902,466.30. The trade was a 5.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 41,728 shares of company stock worth $402,649. 7.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock valued at $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Arvinas by 109.4% during the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock worth $49,000 after purchasing an additional 3,500 shares during the last quarter. Jain Global LLC acquired a new stake in shares of Arvinas in the 3rd quarter valued at $95,000. Oxford Asset Management LLP boosted its holdings in shares of Arvinas by 15.5% in the 2nd quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after purchasing an additional 2,242 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Arvinas in the 3rd quarter valued at $124,000. 95.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. BTIG Research boosted their price objective on Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Weiss Ratings downgraded Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Stephens reiterated an “overweight” rating and set a $18.00 price objective on shares of Arvinas in a research report on Wednesday, June 3rd. Citigroup increased their price objective on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Finally, Barclays boosted their target price on shares of Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $15.42.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.